Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 14, 2020AgingOpen Access

Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHao WangGYGuang YangQZQian Zhang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2020) studied this question.

synapsesocial.com/papers/6a94377fa09a696dc39c505dhttps://doi.org/10.18632/aging.103665
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases2010 · 171 citations
  2. 2Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury2016 · 68 citations
  3. 3Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity <i>in vitro</i> and in a model of psoriasis2009 · 407 citations
  4. 4Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach2008 · 223 citations